News

Governor Northam Grants $3.4 Million to Advance Research Commercialization

Governor Ralph Northam today announced that 34 small technology-focused businesses in Virginia will receive a total of $3.4 million in Commonwealth Commercialization Fund (CCF) grants to commercialize research in an array of sectors, including agricultural and environmental technologies, autonomous systems, clean energy, cybersecurity, data analytics, life sciences, and space and satellites. These awards mark the inaugural funding round for CCF, which was developed through the Virginia Innovation Partnership Authority (VIPA).

“Facilitating research breakthroughs and getting new technologies out of the lab and into the hands of consumers is key to driving economic growth and creating jobs in the Commonwealth,” said Governor Northam. “I am confident this first round of CCF awards will produce far-reaching benefits and congratulate these innovators and entrepreneurs on their success in developing transformative solutions to improve lives and address some of the most pressing challenges we face.”

CCF was launched in 2020 to promote innovative and collaborative commercialization efforts, consolidating two legacy programs, the Commonwealth Research Commercialization Fund and the Virginia Research Investment Fund. The Fiscal Year 2021 round offered grants of up to $100,000 to advance early-stage technology projects in strategically important industries through product or service development, market research, intellectual property protection, marketing, pilots, and more. Award recipients will provide 1:1 match funding.

“The new Commonwealth Commercialization Fund signals Virginia’s commitment to increasing commercialization outcomes for small Virginia businesses across many industries,” said Secretary of Commerce and Trade Brian Ball. “Early funding is essential in bringing new products and innovations to market and we look forward to watching the awardees’ innovations thrive in the Commonwealth.”

“We are excited to announce these awards from this first solicitation of CCF,” said Bob Stolle, President of VIPA. “VIPA was created to be a catalyst for expanding innovation and entrepreneurship in Virginia with a clear goal of accelerating scientific, technology-based research and commercialization. These awards are just the beginning of our work with companies, universities, and research institutes to advance research from proof-of-concept to commercialization.”

CCF seeks technologies with a high potential for economic development and job creation and that position the Commonwealth as a national leader in science- and technology-based research, development, and commercialization. For more information about the CCF program, visit cit.org/ccf.

A few companies receiving the CCF projects awards, contingent upon acceptance of award terms and conditions, include:

AgroSpheres, Inc. | Mr. Ameer Shakeel
Commercialization of Reliable, Sustainable Crop Protection Products, $100,000, Agricultural and Environmental Technologies, Charlottesville

BEAM Diagnostics, Inc | Dr. Sarah Snider
Commercialization of Beacon: A Digital Platform for Innovative Prediction Tools in Healthcare, $100,000, Life and Health Sciences, Roanoke

Bonumose, Inc. | Mr. Edwin Rogers
Making Healthy Sugar Affordable for the Mass Market, $100,000, Life and Health Sciences, Charlottesville

Cerillo, Inc. | Mr. Kevin Seitter
Development of a Low-Cost, Miniaturized, Field-Deployable ELISA Reader, $100,000, Life and Health Sciences, Charlottesville

Contraline, Inc | Mr. Kevin Eisenfrats
Development of Market Access Strategy for a Novel Male Contraceptive, $99,998, Life and Health Sciences, Charlottesville

Jeeva Informatics Solutions Inc | Mr. Harsha Rajasimha
Remote Touchless Patient Recruitment and Retention Platform for Clinical Research, $100,000, Life and Health Sciences, Vienna

Meru Biotechnologies | Dr. Daniel Rodenhaver
Development and Commercialization of TruBind Technology for Drug Discovery, $95,850, Life and Health Sciences, Richmond

Recent News

12/11/2024

Liquet™ Medical Inc. Receives FDA 510(k) Clearance for the Versus™ Catheter

Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Versus™ Catheter. This innovative medical device is set to enhance the treatment of pulmonary artery blood clots by offering real-time pulmonary artery

12/03/2024

ivWatch Named to Inc.’s 2024 Best in Business List in Health Products Category

ivWatch, LLC, the IV safety company, is proud to announce it has been named to the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large.

12/03/2024

New Report Finds Bioscience Sector Generates Over $3 Trillion for U.S. Economy

The Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic performance, its impacts, and its geographic footprint. The report, “The U.S. Bioscience Economy: Driving Economic Growth and Opportunity in States and Regions,” analyzes the sector’s economic impact via employment, overall